Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human αvβ3 integrin

Journal of Molecular Biology

Volumn 326, Issue 5, 2003, Pages 1475-1488

  Richards, Julie ^a   Miller, Michelle ^a   Abend, Johanna ^a   Koide, Akiko ^a,b   Koide, Shohei ^a,b   Dewhurst, Stephen ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Fibronectin type III domain; Integrin; Phage display; RGD; Scaffold

Indexed keywords

ALANINE; BINDING PROTEIN; CELL SURFACE RECEPTOR; FIBRONECTIN; FIBRONECTIN TYPE III; GLUTAMIC ACID; INTEGRIN; MONOCLONAL ANTIBODY; SCLEROPROTEIN; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR CELL; UPREGULATION;

EID: 0037424598     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(03)00082-2     Document Type: Article

References (42)

1. Wilson D.R., Finlay B.B. Phage display: applications, innovations, and issues in phage and host biology. Can. J. Microbiol. 44:1998;313-329.
2. Sidhu S.S. Phage display in pharmaceutical biotechnology. Curr. Opin. Biotechnol. 11:2000;610-616.
3. Lowman H.B. Bacteriophage display and discovery of peptide leads for drug development. Annu. Rev. Biophys. Biomol. Struct. 26:1997;401-424.
4. O'Neil K.T., Hoess R.H., Jackson S.A., Ramachandran N.S., Mousa S.A., DeGrado W.F. Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. Proteins: Struct. Funct. Genet. 14:1992;509-515.
5. Main A.L., Harvey T.S., Baron M., Boyd J., Campbell I.D. The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Cell. 71:1992;671-678.
6. Carr P.A., Erickson H.P., Palmer A.G. III. Backbone dynamics of homologous fibronectin type III cell adhesion domains from fibronectin and tenascin. Structure. 5:1997;949-959.
7. Koide A., Bailey C.W., Huang X., Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J. Mol. Biol. 284:1998;1141-1151.
8. Weiss J.M., Renkl A.C., Maier C.S., Kimmig M., Liaw L., Ahrens T., et al. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J. Expt. Med. 194:2001;1219-1229.
9. Horton M.A. The alpha v beta 3 integrin "vitronectin receptor" Int. J. Biochem. Cell. Biol. 29:1997;721-725.
10. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., Cheresh D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 270:1995;1500-1502.
11. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 85:1996;683-693.
12. Silletti S., Kessler T., Goldberg J., Boger D.L., Cheresh D.A. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl Acad. Sci. USA. 98:2001;119-124.
13. Kozlova N.I., Morozevich G.E., Chubukina A.N., Berman A.E. Integrin alphavbeta3 promotes anchorage-dependent apoptosis in human intestinal carcinoma cells. Oncogene. 20:2001;4710-4717.
14. Chatterjee S., Matsumura A., Schradermeier J., Gillespie G.Y. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J. Neurooncol. 46:2000;135-144.
15. Chatterjee S., Brite K.H., Matsumura A. Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides. Clin. Cancer Res. 7:2001;3006-3011.
16. Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96:1995;1815-1822.
17. Sipkins D.A., Cheresh D.A., Kazemi M.R., Nevin L.M., Bednarski M.D., Li K.C. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nature Med. 4:1998;623-626.
18. Hufton S.E., van Neer N., van den Beuken T., Desmet J., Sablon E., Hoogenboom H.R. Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands. FEBS Letters. 475:2000;225-231.
19. Kumar C.C., Nie H., Rogers C.P., Malkowski M., Maxwell E., Catino J.J., Armstrong L. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. J. Pharmacol. Expt. Ther. 283:1997;843-853.
20. Blystone S.D., Graham I.L., Lindberg F.P., Brown E.J. Integrin alpha v beta 3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor alpha 5 beta 1. J. Cell. Biol. 127:1994;1129-1137.
21. McLane M.A., Vijay-Kumar S., Marcinkiewicz C., Calvete J.J., Niewiarowski S. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. FEBS Letters. 391:1996;139-143.
22. Hantgan R.R., Endenburg S.C., Cavero I., Marguerie G., Uzan A., Sixma J.J., de Groot P.G. Inhibition of platelet adhesion to fibrin(ogen) in flowing whole blood by Arg-Gly-Asp and fibrinogen gamma-chain carboxy terminal peptides. Thromb. Haemost. 68:1992;694-700.
23. Scarborough R.M., Rose J.W., Naughton M.A., Phillips D.R., Nannizzi L., Arfsten A., et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J. Biol. Chem. 268:1993;1058-1065.
24. Marcinkiewicz C., Taooka Y., Yokosaki Y., Calvete J.J., Marcinkiewicz M.M., Lobb R.R., et al. Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin alpha 9beta 1 with VCAM-1, tenascin-C, and osteopontin. J. Biol. Chem. 275:2000;31930-31937.
25. Koivunen E., Wang B., Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J. Cell. Biol. 124:1994;373-380.
26. Oldenburg K.R., Loganathan D., Goldstein I.J., Schultz P.G., Gallop M.A. Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc. Natl Acad. Sci. USA. 89:1992;5393-5397.
27. Smith J.W., Tachias K., Madison E.L. Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin alpha IIb beta 3. J. Biol. Chem. 270:1995;30486-30490.
28. Tani P.H., Loftus J.C., Bowditch R.D. In vitro selection of fibronectin gain-of-function mutations. Biochem. J. 365:2002;287-294.
29. Altroff H., van der Walle C.F., Asselin J., Fairless R., Campbell I.D., Mardon H.J. The eighth FIII domain of human fibronectin promotes integrin alpha5beta1 binding via stabilization of the ninth FIII domain. J. Biol. Chem. 276:2001;38885-38892.
30. Pampori N., Hato T., Stupack D.G., Aidoudi S., Cheresh D.A., Nemerow G.R., Shattil S.J. Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand. J. Biol. Chem. 274:1999;21609-21616.
31. Dickinson C.D., Veerapandian B., Dai X.-P., Hamlin R.C., Xuong N.-H., Ruoslahti E., Ely K.R. Crystal structure of the tenth type III cell adhesion module of human fibronectin. J. Mol. Biol. 236:1994;1079-1092.
32. Xiong J.P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L., et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science. 294:2001;339-345.
33. Xiong J.P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., Arnaout M.A. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science. 296:2002;151-155.
34. Suzuki S., Huang Z.S., Tanihara H. Cloning of an integrin beta subunit exhibiting high homology with integrin beta 3 subunit. Proc. Natl Acad. Sci. USA. 87:1990;5354-5358.
35. Haisma H.J., Grill J., Curiel D.T., Hoogeland S., van Beusechem V.W., Pinedo H.M., Gerritsen W.R. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther. 7:2000;901-904.
36. Wickham T.J., Haskard D., Segal D., Kovesdi I. Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol. Immunother. 45:1997;149-151.
37. Wickham T.J., Segal D.M., Roelvink P.W., Carrion M.E., Lizonova A., Lee G.M., Kovesdi I. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 70:1996;6831-6838.
38. Hart S.L. Integrin-mediated vectors for gene transfer and therapy. Curr. Opin. Mol. Ther. 1:1999;197-203.
39. Kraulis P. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallog. 24:1991;946-950.
40. Chappel J.A., He M., Kang A.S. Modulation of antibody display on M13 filamentous phage. J. Immunol. Methods. 221:1998;25-34.
41. Kunkel T.A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl Acad. Sci. USA. 82:1985;488-492.
42. Koivunen E., Wang B., Dickinson C.D., Ruoslahti E. Peptides in cell adhesion research. Methods Enzymol. 245:1994;346-369.